BNC KOREA, Inc.

256840 KRX Pharmaceuticals Pharmaceuticals
KOSDAQ
₩2,585.00
-1.52%
Delayed · cached 15 min

Fair value analysis

256840
BNC KOREA, Inc.
PharmaceuticalsPharmaceuticals
₩2,585.00
Close used for this calculation
₩982.72Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
32/100
Profitability4/25
Returns0/25
Balance Sheet23/25
Efficiency5/25
Growth3/25
Weak
Quality radar
32Prof.4/25Ret.0/25Eff.5/25B.Sht23/25Growth3/25

Consensus fair value

₩982.72
Above FV
▼ -62.0% against the close used
Model range ₩55.77 – ₩1,792.83
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩55.77Fair value₩982.72Bull₩1,792.83
FairClose
52-week traded range
52W low ₩2,170.0052W high ₩6,050.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

BNC KOREA, Inc. closed at ₩2,585.00, 163.0% above the consensus fair value of ₩982.72 drawn from 7 valuation models.

Financial DNA score 32/100 — Weak. P/E of 61.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩55.77
-97.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩1,792.83
-30.6%
√(22.5 × EPS × BVPS)
EPS=42, BVPS=3401.32 · outside Graham range (P/E 61.6, P/B 0.8) — asset-light, treat as a rough floor
P/E Fair Value
₩840.00
-67.5%
EPS × 20x (sector P/E)
EPS=42, Sector P/E=20x
Dividend Discount (DDM)
₩494.38
-80.9%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=38.78, r=10%, g=2%
Book Value (P/B)
₩411.56
-84.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=3401.32, ROE=1.2%, g=3%, r=10%
Reverse DCF
₩2,585.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 22.4% | Historical: 0%
Margin of Safety
₩672.15
-74.0%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=896.2, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.